Proceedings Of AGM Held On September 29, 2026.
CCME Global Ltd operates in Biotechnology within the Healthcare sector.
385 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Standalone figures
| Ratio | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross margin % | — | — | — | — | — | — | — | — |
| EBITDA margin % | — | — | — | — | — | — | — | — |
| EBIT margin % | — | — | — | — | — | — | — | — |
| PAT margin % | — | — | — | — | — | — | — | — |
| Working capital | ||||||||
| Receivable days | — | — | — | — | — | — | — | — |
| Inventory days | — | — | — | — | — | — | — | — |
| Payable days | — | — | — | — | — | — | — | — |
| NWC days | — | — | — | — | — | — | — | — |
| Leverage | ||||||||
| Current ratio | — | — | 76.67 | 69.92 | 64.07 | 28.94 | — | 8.65 |
| Debt to EBITDA | — | — | — | — | — | — | — | — |
| Debt to equity | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest coverage | — | — | — | — | — | — | — | — |
| Asset turnover | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Return ratios | ||||||||
| Return on assets % | — | — | -1.3% | -1.3% | -1.6% | -72.9% | 39.6% | -1.6% |
| Return on capital employed % | — | — | -1.3% | -1.3% | -1.6% | -54.8% | 50.6% | -2.9% |
| Return on equity % | — | — | -1.3% | -1.3% | -1.6% | -75.5% | 41% | -1.8% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 11.33% | 74.17% | 74.35% | |
| FII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 88.67% | 88.67% | 88.67% | 88.67% | 88.67% | 88.67% | 88.67% | 88.67% | 88.67% | 88.67% | 25.83% | 25.65% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 1,736 | 1,855 | 1,938 | 1,937 |
Promoter holding up 63.02 percentage points since Sep 2023.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
No scheme among the 32 fund houses on record reported a position in CCME Global Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Documents link to external sources (exchange filings, company investor pages).
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Anthem Biosciences LimitedANTHEMANTHEM | ₹48,213 Cr | ₹48,264 Cr | ₹2,002 Cr | ₹793 Cr | 39.3% | ₹576 Cr | 27.9% | 27.6% | 19.5% | 124 |
| Advanced Enzyme Technologies LimitedADVENZYMESADVENZYMES | ₹3,072 Cr | ₹3,092 Cr | ₹750 Cr | ₹224 Cr | 30.7% | ₹166 Cr | 23.3% | 13.7% | 11.1% | 331 |
| CCME Global LtdCCMECCME | ₹54 Cr | ₹54 Cr | ₹0 Cr | ₹0 Cr | — | ₹4 Cr | — | -2.9% | -2.9% | — |
| Vivo Bio Tech LtdVIVOBIOTVIVOBIOT | ₹38 Cr | ₹92 Cr | ₹47 Cr | ₹21 Cr | 44% | ₹7 Cr | 15.6% | 15.2% | 11% | 517 |
| Shree Ganesh Biotech (India) LtdSHREEGANESSHREEGANES | ₹19 Cr | ₹19 Cr | ₹23 Cr | ₹-1 Cr | -19.3% | ₹0 Cr | 7.7% | 0.8% | 0.6% | 846 |
| Genomic Valley Biotech LtdGVBLGVBL | ₹9 Cr | ₹9 Cr | ₹0 Cr | ₹-0 Cr | 14.8% | ₹-1 Cr | 11.1% | 1% | 0.8% | 3,565 |
Proceedings Of AGM Held On September 29, 2026.
Scrutinizer''s Report And Voting Results For The AGM Held On September 29, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Announcement under Regulation 30 (LODR)-Preferential Issue
Announcement under Regulation 30 (LODR)-Change in Directorate
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
| 29 Sept 2026, 10:59 pm | AGM/EGM AGM | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 29 Sept 2026, 10:50 pm | Company Update Amendments to Memorandum & Articles of Association | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association |
| 29 Sept 2026, 10:42 pm | Company Update Preferential Issue | Announcement under Regulation 30 (LODR)-Preferential Issue |
| 29 Sept 2026, 10:35 pm | Company Update Change in Directorate | Announcement under Regulation 30 (LODR)-Change in Directorate |
| 29 Sept 2026, 10:33 pm | Company Update Change in Management | Announcement under Regulation 30 (LODR)-Change in Management |
| 29 Sept 2026, 10:31 pm | Company Update Appointment of Statutory Auditor/s | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s |
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| — | — | — | — | — | 0 | 0 | 0 | 4 | 0 | 1 | |
| — | — | — | — | — | -0 | -0 | -0 | -4 | -0 | -1 | |
| OPM % | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| — | — | — | — | — | 0 | 0 | 0 | 0 | 4 | 0 | |
| Profit before tax | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -4 | 4 | -1 |
| Tax | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -4 | 4 | -1 | |
| PAT margin % | — | — | — | — | — | — | — | — | — | — | — |
| EPS (₹) | 0.4 | -0 | -0.2 | — | -0.1 | -0.1 | — | — | -2.9 | 2.7 | -0.5 |
| EPS adjusted (₹) | — | — | — | — | — | -0.1 | -0.1 | -0.1 | -2.9 | 2.7 | -0.2 |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 13 | 13 | 13 | 13 | 13 | 45 |
| Reserves | -4 | -4 | -4 | -8 | -4 | -5 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 5 | |
| Total equity & liabilities | 9 | 9 | 9 | 5 | 9 | 45 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | — | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | 9 | 9 | 5 | 9 | 45 | |
| Total assets | 9 | 9 | 9 | 5 | 9 | 45 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| -0 | -0 | -0 | 0 | 0 | 5 | |
| — | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 32 | |
| Net cash flow | — | 0 | 0 | 0 | 0 | 37 |
| Free cash flow | — | — | — | 0 | 0 | 5 |
| CFO / Operating profit % | — | — | — | — | — | — |